Relations Between Recurrence Risk Perceptions and Fear of Cancer Recurrence in Breast Cancer Survivors
Overview
Authors
Affiliations
Purpose: This study aimed to: (1) determine the accuracy of Dutch breast cancer survivors' estimations of the locoregional recurrence risk (LRR); (2) examine which variables influence (the accuracy of) risk estimations, and risk appraisals; and (3) investigate the influence of the objective LRR risk (estimated using the INFLUENCE-nomogram), risk estimations and risk appraisals on fear of cancer recurrence (FCR). Findings of this study will inform clinicians on risk communication and can improve communication about FCR.
Methods: In a cross-sectional survey among 258 breast cancer survivors, women's recurrence risk estimations (in odds) and risk appraisals (in high/low), FCR, demographics and illness perceptions, about one year after surgery were measured and compared to the objective risk for LRRs estimated using the INFLUENCE-nomogram.
Results: Half of the women (54%) accurately estimated their LRR risk, 34% underestimated and 13% overestimated their risk. Risk estimations and risk appraisals were only moderately positively correlated (r = 0.58). Higher risk appraisals were associated with radiotherapy (r = 0.18) and having weaker cure beliefs (r = - 0.19). Younger age was associated with overestimation of risk (r = - 0.23). Recurrence risk estimations and risk appraisals were associated with more FCR (r = 0.29, r = 0.39). In regression, only risk appraisal contributed significantly to FCR.
Conclusion: Although women were fairly accurate in recurrence risk estimations, it remains difficult to predict over- or underestimation. Recurrence risk estimations and risk appraisal are two different concepts which are both associated with FCR and should therefore be addressed in patient-provider communication.
Lei R, Zhang M, Gui G, Yang D, He L Front Public Health. 2025; 13:1524492.
PMID: 40051512 PMC: 11882430. DOI: 10.3389/fpubh.2025.1524492.
Yu K, Gao H, Liu S, Yao H, Wang X, Luo C Rheumatol Adv Pract. 2024; 9(1):rkae148.
PMID: 39717021 PMC: 11665928. DOI: 10.1093/rap/rkae148.
Rosenberg S, Zheng Y, Santos K, Riley E, Meadows H, Snow C Breast Cancer Res Treat. 2024; 209(3):513-520.
PMID: 39432162 DOI: 10.1007/s10549-024-07510-8.
Wahab S, Joshua A, Dhillon H, Barnet M J Cancer Surviv. 2024; .
PMID: 39141308 DOI: 10.1007/s11764-024-01655-7.
Stafford L, Sinclair M, Butow P, Hughes J, Park A, Gilham L Breast Cancer Res Treat. 2023; 201(3):367-376.
PMID: 37480383 PMC: 10460737. DOI: 10.1007/s10549-023-07039-2.